These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 28592156)
41. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma]. Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123 [TBL] [Abstract][Full Text] [Related]
42. Advances in the management of asymptomatic myeloma. Mateos MV Curr Opin Oncol; 2014 Nov; 26(6):670-6. PubMed ID: 25210868 [TBL] [Abstract][Full Text] [Related]
43. Smoldering multiple myeloma: to treat or not to treat. Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Martino M; Morabito F; Gentili S Expert Opin Pharmacother; 2015 Apr; 16(6):785-90. PubMed ID: 25659943 [TBL] [Abstract][Full Text] [Related]
44. Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials. Ojo AS; Akinyemi O; Araoye MO; Ali A Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e27-e40. PubMed ID: 36402701 [TBL] [Abstract][Full Text] [Related]
45. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies. Sandecka V; Popkova T; Stork M; Maisnar V; Minarik J; Jungova A; Pavlicek P; Stejskal L; Pospisilova L; Heindorfer A; Obernauerova J; Gregora E; Sykora M; Ullrychova J; Wrobel M; Kessler P; Jelinek T; Kunovszki P; Bathija S; Gros B; Wilbertz S; Cai Q; Lam A; Spicka I Blood Cancer J; 2023 Sep; 13(1):153. PubMed ID: 37752128 [TBL] [Abstract][Full Text] [Related]
46. Smoldering multiple myeloma. Gao M; Yang G; Kong Y; Wu X; Shi J Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300 [TBL] [Abstract][Full Text] [Related]
47. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830 [TBL] [Abstract][Full Text] [Related]
57. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288 [TBL] [Abstract][Full Text] [Related]
58. Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. Manier S; Salem KZ; Liu D; Ghobrial IM Am Soc Clin Oncol Educ Book; 2016; 35():e400-6. PubMed ID: 27249747 [TBL] [Abstract][Full Text] [Related]
59. Is aggressive treatment of smoldering myeloma the path to curing myeloma? Chakraborty R; Al Hadidi S; Cliff ERS; Mohyuddin GR Blood Adv; 2023 Aug; 7(15):3932-3935. PubMed ID: 37196639 [No Abstract] [Full Text] [Related]
60. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Atrash S; Robinson M; Slaughter D; Aneralla A; Brown T; Robinson J; Ndiaye A; Sprouse C; Zhang Q; Symanowski JT; Friend R; Voorhees PM; Usmani SZ; Bhutani M Blood Cancer J; 2018 Nov; 8(11):107. PubMed ID: 30410066 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]